NRX Pharmaceuticals Inc（NRXP）财务数据NRXPNRX Pharmaceuticals Inc

Evaluating the bottom line, NRX Pharmaceuticals Inc maintains a gross margin of 35.02%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -444.57%, while the net margin is -133.90%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively NRXP converts its operational activities into shareholder value.

In the context of the broader market, NRXP competes directly with industry leaders such as OKUR and TNYA. With a market capitalization of $156.73M, it holds a significant position in the sector. When comparing efficiency, NRXP's gross margin of 35.02% stands against OKUR's N/A and TNYA's 100.00%. Such benchmarking helps identify whether NRX Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin improvement, reaching 54.22% in Q4 2025, while total revenue is projected to increase significantly in upcoming quarters, reaching $1.1 million in Q1 2026.